Changing the Face of Oral Cancer Testing
Welcome to Wisdom Bioscience
About
Wisdom Bioscience, is a genomics-driven diagnostics company focused on transforming the early detection of oral cancer. Founded in 2024 and located in Irvine, California, and Daresbury UK, the company is developing a scalable molecular diagnostics platform that integrates next-generation sequencing (NGS) and non-invasive sample collection into routine dental care. Wisdom Bioscience’s approach is designed to enable earlier detection of disease, improve clinical outcomes, and expand access to cancer screening through existing healthcare infrastructure. Beyond its initial oral cancer application, the company’s platform has the potential to support future diagnostic and screening solutions across additional disease areas.
Advancing Oral Cancer Diagnosis
Oral Cancer
Oral cancer remains one of the most underdiagnosed cancers, with outcomes highly dependent on when the cancer is detected. Current screening methods rely largely on visual examination, which can miss disease at an early stage.
Cancer Testing
Cancer testing remains the most important lever for reducing oncology patient burden, find it early, treat it earlier. Existing cancer testing can be difficult to access due to high cost, ineffective delivery, and uncertain reimbursement or funding.
Our Approach
Wisdom Bioscience introduces a new approach — combining whole genome sequencing with a simple buccal swab collected during routine dental visits to identify clinically relevant genetic markers associated with oral cancer. Built around established biomarkers and reimbursement pathways, the platform is designed for real-world adoption across dental practices.
A new approach to Oral Cancer Testing
Early, more accurate detection of oral cancer using the power of genomics science delivered through routine dental care.
Wisdom Bioscience offers a state-of-the-art oral cancer test that can detect early signs of this devastating disease. Our advanced diagnostic technology provides accurate and reliable results.
Wisdom Bioscience Leadership Team
Hayden Jeffreys - Chief Executive Officer
Hayden Jeffreys - Chief Executive Officer
Hayden Jeffreys - Chief Executive Officer
25 years’ clinical diagnostics industry experience including public and private markets, specializing in molecular diagnostics, including:
- NED of Calbiotech Inc, Invitron & Advisor to Biolyph Inc
- Former COO of Yourgene Health & Cambridge Epigenetix
- CEO of Erba Diagnostics Inc & Head of BD and Strategy at ERBA Group.
Si Hyun Kim - Chief Scientific Officer
Hayden Jeffreys - Chief Executive Officer
Hayden Jeffreys - Chief Executive Officer
Experienced scientific leader, with more than 15 years of expertise in molecular biology, assay and technology development.
Scientist, Genentech
- Barcoded NGS development
- Outsourcing Management
Staff Scientist, Q2 Solutions
- Genomic assay development
- Laboratory automation
Vern Norviel - General Counsel
Hayden Jeffreys - Chief Executive Officer
Dr. Aditya Rajagopal - Chairperson
Vern has four decades counseling innovative life sciences companies and working closely with them to develop successful business and IP strategies. In his legal practice, he has represented a wide variety of companies, as well as venture capital firms, in areas such as therapeutics, diagnostics, nanotechnology, genomics, proteomics, and p
Vern has four decades counseling innovative life sciences companies and working closely with them to develop successful business and IP strategies. In his legal practice, he has represented a wide variety of companies, as well as venture capital firms, in areas such as therapeutics, diagnostics, nanotechnology, genomics, proteomics, and personalized medicine. He has also served as a founder, and business counselor to a range of life science companies, including Affymetrix, which he took public ($10B IPO). Vern is recognized among the country's top life sciences attorneys in Chambers USA: America's Leading Lawyers for Business. A fun fact about Vern: his interest in the field of personalized medicine prompted him to become the first attorney to have had his/her entire genome sequenced and made available in a public database. He have served on a number of boards of academic institutions and life science institutions in neurology, oncology, and related human and animal health organizations. In academics, he has served as an adjunct professor in biotechnology for over 14 years.
Dr. Aditya Rajagopal - Chairperson
Prof. Scott E Fraser - Senior Advisor
Dr. Aditya Rajagopal - Chairperson
Executive Chairman of Wisdom Biosciences
- CEO of EspertoMedical, a Caltech spin-out building physiometricmonitors.
- Founder and Chairman of ChromaCode, a revenue stage oncology Dx Company
- Part-time faculty at Caltech and USC, formerly venture partner at ND Capital
Prof. Scott E Fraser - Senior Advisor
Prof. Scott E Fraser - Senior Advisor
Prof. Scott E Fraser - Senior Advisor
Professor Scott E. Fraser has a long-standing commitment to quantitative biology, applying the tools of chemistry, engineering, and physics to problems in fields ranging from developmental biology to medicine.
He has served on the faculties of UC Irvine, Caltech & USC, and now is the Vice President of the CZI, one of the largest science philanthropies.